Market Overview:
The global Janus kinase (JAK) inhibitors market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of autoimmune disorders and oncology, and the rising demand for targeted therapies. The JAK inhibitors market is segmented by type into ruxolitinib, tofacitinib, oclacitinib, baricitinib, and peficitinib. By application, it is segmented into autoimmune disorders and oncology. Geographically, it is segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa .Some of the key players operating in this market are AbbVie Inc., Amgen Inc., AstraZeneca plc., Bayer AG,, Bristol-Myers Squibb Company,, Eli Lilly and Company,, F Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG,, Pfizer Inc,.
 Inhibitors Industry Outlook.svg)
Product Definition:
A Janus kinase inhibitor is a type of drug that blocks the action of the Janus kinases. These drugs are used to treat diseases such as rheumatoid arthritis, psoriasis, and cancer.
Ruxolitinib:
Ruxolitinib (Myricetinib) is a small molecule developed by the pharmaceutical company Eisai. It was first discovered in plant species, and later on it was identified that this compound has high potential in treating cancer cells. Ruxolitinib is currently under phase II clinical trials for the treatment of Non-Small Cell Lung Cancer (NSCLC), with positive Phase I & III results having been reported thus far.
Tofacitinib:
Tofacitinib (Xeloda) is a novel oral JAK inhibitor developed by Eli Lilly and Company. Tofacitinib was approved by the FDA in March 2016 for treatment of patients with metastatic non-small cell lung cancer (NSCLC), who have received one or more chemotherapy regimens. Chemotherapy includes multi-agent chemotherapy, anthracycline therapy, and tyrosine kinase inhibitors.
Application Insights:
On the basis of application, the global Janus kinase (JAK) inhibitors market is segmented into autoimmune disorders and oncology. The autoimmune disorders segment dominated the overall market in terms of revenue share in 2017. Increasing prevalence of chronic diseases, such as rheumatoid arthritis, psoriasis, diabetes mellitus type 2 & 3 and many others is expected to be a high impact rendering driver for this growth during the forecast period.
The oncology segment is anticipated to witness significant growth over the forecast period owing to increasing cancer cases globally coupled with rising awareness about early diagnosis and treatment options. For instance, according to data published by WHO in 2018 regarding cancer incidence worldwide; it has been estimated that around 1 million new cases were diagnosed worldwide every year along with nearly 870 thousand deaths due to cancer which represented an increase from 2014 when 584 thousand people died due these diseases globally.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives, and increasing healthcare expenditure are some of the factors responsible for its growth. For instance, in May 2018, Novartis AG & Co. announced to invest USD X million over a period of four years on cancer care by supporting research and development activities aimed at finding new treatment options for patients with cancer.
Asia Pacific is expected to be one of the fastest growing regions during the forecast period owing to rising disposable income levels and improving economic conditions in emerging countries such as China.
Growth Factors:
- Increasing prevalence of autoimmune diseases: The global autoimmune diseases market is expected to grow at a CAGR of 7.8% from 2016 to 2021, reaching a value of 1.3 billion by 2021. This growth is attributed to the increasing prevalence of autoimmune diseases, rising awareness about these conditions, and technological advancements in the diagnosis and treatment of these disorders.
- Growing demand for targeted therapies: The demand for targeted therapies is growing due to their better efficacy and fewer side effects as compared to traditional therapies. JAK inhibitors are targeted therapies that offer an efficacious treatment option for patients with autoimmune diseases who do not respond well or cannot tolerate traditional treatments such as steroids and nonsteroidal anti-inflammatory drugs (NSAIDs).
- Rising R&D investments in JAK inhibitors: There has been a significant increase in R&D investments in JAK inhibitors over the past few years owing to the promising clinical results obtained with these drugs thus far. This is likely to result in more novel JAK inhibitors being approved for use in the near future, thereby driving market growth further..
Scope Of The Report
Report Attributes
Report Details
Report Title
Janus Kinase (JAK) Inhibitors Market Research Report
By Type
Ruxolitinib, Tofacitinib, Oclacitinib, Baricitinib, Peficitinib
By Application
Autoimmune Disorders, Oncology
By Companies
Astellas Pharma, Inc., Eli Lilly and Co., Incyte Corp., Novartis AG, Pfizer Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
213
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Janus Kinase (JAK) Inhibitors Market Report Segments:
The global Janus Kinase (JAK) Inhibitors market is segmented on the basis of:
Types
Ruxolitinib, Tofacitinib, Oclacitinib, Baricitinib, Peficitinib
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Autoimmune Disorders, Oncology
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma, Inc.
- Eli Lilly and Co.
- Incyte Corp.
- Novartis AG
- Pfizer Inc.
 Inhibitors Market Overview.svg)
Highlights of The Janus Kinase (JAK) Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Ruxolitinib
- Tofacitinib
- Oclacitinib
- Baricitinib
- Peficitinib
- By Application:
- Autoimmune Disorders
- Oncology
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Janus Kinase (JAK) Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Inhibitors Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Janus kinase inhibitors (JAK inhibitors) are medications that block the activity of Janus kinases. These enzymes play a role in cell signaling and can be overactive in some cancers. JAK inhibitors can help to treat various types of cancer, including leukemia, lymphoma, and multiple myeloma.
Some of the key players operating in the janus kinase (jak) inhibitors market are Astellas Pharma, Inc., Eli Lilly and Co., Incyte Corp., Novartis AG, Pfizer Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Janus Kinase (JAK) Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Janus Kinase (JAK) Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Janus Kinase (JAK) Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Janus Kinase (JAK) Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Janus Kinase (JAK) Inhibitors Market Size & Forecast, 2018-2028
4.5.1 Janus Kinase (JAK) Inhibitors Market Size and Y-o-Y Growth
4.5.2 Janus Kinase (JAK) Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Janus Kinase (JAK) Inhibitors Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Janus Kinase (JAK) Inhibitors Market Size Forecast by Type
5.2.1 Ruxolitinib
5.2.2 Tofacitinib
5.2.3 Oclacitinib
5.2.4 Baricitinib
5.2.5 Peficitinib
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Janus Kinase (JAK) Inhibitors Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Janus Kinase (JAK) Inhibitors Market Size Forecast by Applications
6.2.1 Autoimmune Disorders
6.2.2 Oncology
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Janus Kinase (JAK) Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Janus Kinase (JAK) Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Janus Kinase (JAK) Inhibitors Analysis and Forecast
9.1 Introduction
9.2 North America Janus Kinase (JAK) Inhibitors Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Janus Kinase (JAK) Inhibitors Market Size Forecast by Type
9.6.1 Ruxolitinib
9.6.2 Tofacitinib
9.6.3 Oclacitinib
9.6.4 Baricitinib
9.6.5 Peficitinib
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Janus Kinase (JAK) Inhibitors Market Size Forecast by Applications
9.10.1 Autoimmune Disorders
9.10.2 Oncology
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Janus Kinase (JAK) Inhibitors Analysis and Forecast
10.1 Introduction
10.2 Europe Janus Kinase (JAK) Inhibitors Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Janus Kinase (JAK) Inhibitors Market Size Forecast by Type
10.6.1 Ruxolitinib
10.6.2 Tofacitinib
10.6.3 Oclacitinib
10.6.4 Baricitinib
10.6.5 Peficitinib
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Janus Kinase (JAK) Inhibitors Market Size Forecast by Applications
10.10.1 Autoimmune Disorders
10.10.2 Oncology
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Janus Kinase (JAK) Inhibitors Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Janus Kinase (JAK) Inhibitors Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Janus Kinase (JAK) Inhibitors Market Size Forecast by Type
11.6.1 Ruxolitinib
11.6.2 Tofacitinib
11.6.3 Oclacitinib
11.6.4 Baricitinib
11.6.5 Peficitinib
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Janus Kinase (JAK) Inhibitors Market Size Forecast by Applications
11.10.1 Autoimmune Disorders
11.10.2 Oncology
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Janus Kinase (JAK) Inhibitors Analysis and Forecast
12.1 Introduction
12.2 Latin America Janus Kinase (JAK) Inhibitors Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Janus Kinase (JAK) Inhibitors Market Size Forecast by Type
12.6.1 Ruxolitinib
12.6.2 Tofacitinib
12.6.3 Oclacitinib
12.6.4 Baricitinib
12.6.5 Peficitinib
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Janus Kinase (JAK) Inhibitors Market Size Forecast by Applications
12.10.1 Autoimmune Disorders
12.10.2 Oncology
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Janus Kinase (JAK) Inhibitors Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Janus Kinase (JAK) Inhibitors Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Janus Kinase (JAK) Inhibitors Market Size Forecast by Type
13.6.1 Ruxolitinib
13.6.2 Tofacitinib
13.6.3 Oclacitinib
13.6.4 Baricitinib
13.6.5 Peficitinib
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Janus Kinase (JAK) Inhibitors Market Size Forecast by Applications
13.10.1 Autoimmune Disorders
13.10.2 Oncology
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Janus Kinase (JAK) Inhibitors Market: Competitive Dashboard
14.2 Global Janus Kinase (JAK) Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astellas Pharma, Inc.
14.3.2 Eli Lilly and Co.
14.3.3 Incyte Corp.
14.3.4 Novartis AG
14.3.5 Pfizer Inc.
